| 000 | 01704 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516223712.0 | ||
| 264 | 0 | _c20150330 | |
| 008 | 201503s 0 0 eng d | ||
| 022 | _a1873-2518 | ||
| 024 | 7 |
_a10.1016/j.vaccine.2014.07.013 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrey, Sharon E | |
| 245 | 0 | 0 |
_aComparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. _h[electronic resource] |
| 260 |
_bVaccine _cSep 2014 |
||
| 300 |
_a5027-34 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xpharmacology |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Viral _xblood |
| 650 | 0 | 4 | _aAntibody Formation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHemagglutination Inhibition Tests |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfluenza A Virus, H3N2 Subtype |
| 650 | 0 | 4 |
_aInfluenza Vaccines _ximmunology |
| 650 | 0 | 4 |
_aInfluenza, Human _xprevention & control |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPolysorbates _xpharmacology |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 |
_aSqualene _xpharmacology |
| 650 | 0 | 4 | _aVaccine Potency |
| 700 | 1 | _aReyes, Mari Rose Aplasca-De Los | |
| 700 | 1 | _aReynales, Humberto | |
| 700 | 1 | _aBermal, Nancy Nazaire | |
| 700 | 1 | _aNicolay, Uwe | |
| 700 | 1 | _aNarasimhan, Vas | |
| 700 | 1 | _aForleo-Neto, Eduardo | |
| 700 | 1 | _aArora, Ashwani Kumar | |
| 773 | 0 |
_tVaccine _gvol. 32 _gno. 39 _gp. 5027-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2014.07.013 _zAvailable from publisher's website |
| 999 |
_c24027287 _d24027287 |
||